Ultime notizie per Eisai Co (OTC:ESALF) Azioni

Eisai Co Ltd is a specialty and generic drug manufacturing company. The company's business consists of a pharmaceutical business and other businesses. The pharmaceutical business is categorized by region, including Japan, Americas, China, Asia, and Europe, Middle East, and Africa. Eisai also reports a consumer healthcare business for Japan. The vast majority of the company's revenue is derived by its Japanese pharmaceutical business, followed by its Americas pharmaceuticals segment. The company utilizes licensing strategies in order to expand its research, development, manufacturing, and marketing capabilities.

Eisai Co Ltd

Biogen, Eisai new Alzheimer's drug considered too costly in Britain

Eli Lilly Alzheimer's drug set to face same fate as Biogen's in U.K.: report

Healthcare company Eli Lilly's ($LLY) Alzheimer's drug, donanemab (marketed as Kisunla), could be rejected for use by the National Health Service (...

Eli Lilly's Alzheimer's Drug Could be Rejected by NHS

QIAGEN, Lilly to develop Alzheimer's risk detection test

Merck Keytruda with Eisai's Lenvima succeeds in late-stage trial for liver cancer

Eli Lilly's Alzheimer's therapy approved in Japan

Jefferies analyst Stephen Barker maintained a Hold rating on Eisai Co (ESALF – Research Report) yesterday and set a price target of Yen5,500.00. Th...

Comments

Eisai Co

Notizie

Ultime notizie per Eisai Co (OTC:ESALF) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO